Skip to main content
The Globe and Mail
Get full access to globeandmail.com
Support quality journalism
Just $1.99 per week for the first 24 weeks
Just $1.99 per week for the first 24 weeks
The Globe and Mail
Support quality journalism
Get full access to globeandmail.com
Globe and Mail website displayed on various devices
Just$1.99
per week
for the first 24 weeks

var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){console.log("scroll");var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))}pencilInit(".js-sub-pencil",!1);

Neovasc Inc (NVCN-T) Quote - Press Releases

TSX Real-Time Last Sale CAD
Today's Change
Volume
Price Quote as of

More stories below advertisement

Latest Press Releases

Transcatheter Devices Market Size, Share, Applications | Global Report 2026
- Market Prediction - Tue Mar 24, 5:09AM CDT
Market Prediction - CMTX
Tue Mar 24, 5:09AM CDT
In accordance with the study held by Acumen Research, the Transcatheter Devices Market size is projected to reach US$ 19.4 Bn by 2026 with a CAGR of 12% throughout the forecast period 2019 to 2026. The report provides analysis of global Transcatheter Devices Market for the period 2015-2026, wherein 2018 to 2026 is the forecast period and 2018 is considered as the base year.
Neovasc to Report Fourth Quarter and Full Year 2019 Financial Results on March 30, 2020
- Newsfile Corp - Tue Mar 17, 8:03AM CDT
Newsfile Corp - CMTX
Tue Mar 17, 8:03AM CDT
Vancouver, British Columbia--(Newsfile Corp. - March 17, 2020) - (NASDAQ: (TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and minimally invasive devices for the treatment of refractory angina, today announced that it will report financial results for the quarter and year ended December 31, 2019 after the market close on March 30, 2020. Neovasc CEO Fred Colen and CFO Chris Clark will host a conference call to review the company's results at 4:30 PM Eastern Time.
Neovasc to Report Fourth Quarter and Full Year 2019 Financial Results on March 30, 2020
- GlobeNewswire - Tue Mar 17, 8:00AM CDT
GlobeNewswire - CMTX
Tue Mar 17, 8:00AM CDT
via NEWMEDIAWIRE -- Neovasc, Inc. (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and minimally invasive devices for the treatment of refractory angina, today announced that it will report financial results for the quarter and year ended December 31, 2019 after the market close on March 30, 2020. Neovasc CEO Fred Colen and CFO Chris Clark will host a conference call to review the company's results at 4:30 PM Eastern Time.
Global Transcatheter Mitral Valve Repair and Replacement Market Set for Rapid Growth During 2020 - 2025 | Edwards Lifesciences, Medtronic Plc, Abbott Laboratories, Neovasc Inc, etc
- MENAFN - Wed Mar 11, 2:05AM CDT
MENAFN - CMTX
Wed Mar 11, 2:05AM CDT
MENAFN11032020007010647ID1099830997
Global Valvular Heart Disease Treatment Market 2019 Industry Outlook, Comprehensive Insights, Growth and Forecast 2025
- CDN Newswire - Wed Mar 11, 12:59AM CDT
CDN Newswire - CMTX
Wed Mar 11, 12:59AM CDT
, a new addition to the catalog of Fior Markets, provides an overview of the current state of the market and its evolution. The report contains a forecast of 2019 and ending 2025 with key aspects such as supply-demand ratio, dominant players of global Valvular Heart Disease Treatment market, driving factors, restraints, and challenges. The report represents a great amount of information that has been composed using many explanations and subordinate search procedures. Also, the information served in this report has been summarized using rich, methodical, industry-based events.
Neovasc Updates Investors at SVB Leerink 9th Annual Global Healthcare Conference
- Newsfile Corp - Wed Mar 4, 8:01AM CST
Newsfile Corp - CMTX
Wed Mar 4, 8:01AM CST
Vancouver, British Columbia--(Newsfile Corp. - March 4, 2020) - (NASDAQ: NVCN)  (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and minimally invasive devices for the treatment of refractory angina, recaps the presentation by CEO Fred Colen at theSVB Leerink 9th Annual Global Healthcare Conference on Wednesday, February 26, 2020 in New York City.
Neovasc Updates Investors at SVB Leerink 9th Annual Global Healthcare Conference
- GlobeNewswire - Wed Mar 4, 8:00AM CST
GlobeNewswire - CMTX
Wed Mar 4, 8:00AM CST
via NEWMEDIAWIRE -- Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and minimally invasive devices for the treatment of refractory angina, recaps the presentation by CEO Fred Colen at the<b> </b>SVB Leerink 9th Annual Global Healthcare Conference on Wednesday, February 26, 2020 in New York City.
Neovasc Reducer Featured in Peer Reviewed EuroIntervention and PCR Online
- Newsfile Corp - Tue Mar 3, 8:02AM CST
Newsfile Corp - CMTX
Tue Mar 3, 8:02AM CST
Vancouver, British Columbia--(Newsfile Corp. - March 3, 2020) - (NASDAQ: NVCN) (TSX: NVCN) ("Neovasc" or the "Company"), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and minimally invasive devices for the treatment of refractory angina, announced today the Neovasc Reducer™ (the "Reducer") was featured in the peer reviewed publication , the official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI) and highlighted in .
Neovasc Reducer Featured in Peer Reviewed EuroIntervention and PCR Online
- GlobeNewswire - Tue Mar 3, 8:00AM CST
GlobeNewswire - CMTX
Tue Mar 3, 8:00AM CST
via NEWMEDIAWIRE -- Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and minimally invasive devices for the treatment of refractory angina, announced today the Neovasc Reducer(TM) (the "Reducer") was featured in the peer reviewed publication EuroIntervention, the official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI) and highlighted in PCR Online.
Pediatric Asthma Monitor Market Fundamental Analysis By Top Key Players GE Global Research Company, Capnia Inc, Allgene LLC
- Globe News Now - Wed Feb 26, 5:15PM CST
Globe News Now - CMTX
Wed Feb 26, 5:15PM CST
Avail a detailed research offering a comprehensive analysis of the developments, growth outlook, driving factors, and key players of the Pediatric Asthma Monitor market in the latest research report added by Big Market Research.The recent research report on the global presents the latest industry data and future trends, allowing you to recognize the products and end users driving Revenue growth and profitability of the market.

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2020.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies